
## **Supplementary information**

## PARP1 protects from benzo[a]pyrene diol epoxide-induced replication stress and mutagenicity


Jan MF Fischer<sup>§,1,2</sup>, Tabea Zubel<sup>§,1,2</sup>, Kirsten Jander<sup>1</sup>, Jelena Fix<sup>1</sup>, Irmela Trussina<sup>1</sup>, Daniel Gebhard<sup>3</sup>, Jörg Bergemann<sup>3</sup>, Alexander Bürkle<sup>1,\*</sup>, and Aswin Mangerich<sup>1,\*</sup>

<sup>§</sup>Shared first authorship


<sup>1</sup>Molecular Toxicology Group, Department of Biology, University of Konstanz, Germany
<sup>2</sup>Konstanz Research School Chemical Biology, University of Konstanz, Germany
<sup>3</sup>Department of Life Sciences, Albstadt-Sigmaringen University of Applied Sciences, Germany




**Suppl. Fig. 1. Immunochemical analysis of BPDE-induced DNA adducts in HeLa cells. A.** Representative immunofluorescence images of BPDE-DNA adduct staining. Cells were treated with BPDE in concentrations as indicated for 1 h and DNA lesions were detected with a BPDE-DNA specific antibody. **B.** Densitometric quantification of **A**. Depicted are the means of signal intensities of >100 cells, normalized to solvent control. **C.** Slot blot analysis. Cells were treated with BPDE in concentrations as indicated for 1 h. Cellular DNA was extracted, blotted on a nylon membrane and DNA lesions were detected with a BPDE-DNA specific antibody. **D.** Densitometric quantification of the chemiluminescence signal of **C**.




Suppl. Fig. 2. Representative LC-MS/MS chromatograms. HeLa cells were treated with 50 μM BPDE for 1
h. A. Chromatogram of ABT888-untreated cells. B. Representative chromatogram of ABT888-treated cells.




Suppl. Fig. 3. Solvent controls of the Alamar Blue assay. PARP inhibition (A) or genetic ablation (B) of *PARP1* had no influence on cell proliferation and metabolism (n=4). Data represent means  $\pm$  SEM of  $\geq$ 3 independent experiments, each performed in  $\geq$ 3 technical replicates.




Suppl. Fig. 4. PARP inhibition does not affect BPDE-induced cell death. A-C. HeLa cells were treated with increasing concentrations of BPDE. 48 h after exposure, the viability as well as early apoptotic and late apoptotic / necrotic portion of cells was detected by Annexin V / PI staining and flow cytometric analysis. While for BPDE a dose-dependent induction of apoptosis (B) and necrosis (C) could be observed, PARP inhibition had no detectable influence on cell death at the time point analyzed. A-D. Data represent means  $\pm$  SEM of three independent experiments. Statistical evaluation was performed using 2-way ANOVA analysis followed by Sidak's multiple comparison test.




Suppl. Fig. 5. Supplementary data on clonogenic survival assay. A. Quantification of control assays, *i.e.*, solvent control or treated with ABT888. While the presence of solvent (THF/TEA) did not influence colony formation, a weak, yet not significant, decrease was caused by ABT888. B. Quantification of Fig. 4 A. HeLa cells were treated with increasing concentrations of BPDE for 30 min and clonogenic survival assays were performed. Data represent means  $\pm$  SEM of three independent experiments, each performed in technical triplicates. Statistical evaluation was performed using 2-way ANOVA analysis followed by Sidak's multiple comparison testing.



Suppl. Fig. 6. PARP inhibition has no impact on the direct repair of BPDE-DNA adducts. A host cell reactivation assay was performed with a BPDE-treated (75  $\mu$ M) reporter plasmid. After 6 and 24 h the functional reconstitution of plasmids was assessed by analyzing the numbers of cells with reporter gene expression (*dsRed*). PARP inhibition did not alter the cellular NER capacity. Data represent means ± SEM of three independent experiments. Statistical evaluation was performed using 2-way ANOVA analysis followed by Sidak's multiple comparison test.



Suppl. Fig. 7. Analysis of ROS formation upon BPDE treatment. A-B. Dihydroethidium (DHE) was used after BPDE treatment as an indicator for ROS formation. A. Cells were treated with BPDE (10 or 50  $\mu$ M) and after the indicated time points ( $\leq 1$  h) DHE was added and fluorescence was detected. Using a high dose of 50  $\mu$ M BPDE, a weak increase in ROS formation could be observed within the first hour after BPDE treatment. B. Longer exposure (5 h) to BPDE did not result in elevated levels of ROS formation. C. Control treatments for ROS formation (n=3). HeLa Kyoto cells were treated first with the antioxidant N-acetyl cysteine (NAC) and subsequently with the ROS inducer tert-butyl hydroperoxide (TBHP, neg. control) or with TBHP only (pos. control). A dose-dependent increase in ROS levels could be observed with H<sub>2</sub>O<sub>2</sub>. A-C. Data represent means  $\pm$  SEM of three independent experiments, each performed in technical triplicates, normalized to untreated control. Statistical evaluation was performed using 2-way ANOVA analysis followed by Sidak's multiple comparison test. \*\* p>0.01



Suppl. Fig. 8. PARP inhibition influences the BPDE-induced cell cycle delay in unsynchronized HeLa cells. A. Cells were incubated with 10  $\mu$ M ABT888 before and after treatment with increasing concentrations of BPDE for 1 h. Thereafter, cells were cultured for 24 h and cell cycle phase distribution was determined by using PI and analyzing the DNA content. At 100 nM BPDE significant fewer cells were found in G1 phase after 24 h when PARP activity was inhibited. PARP inhibition did not influence the numbers of S phase cells in response to BPDE treatment, but ABT888 treated cells further accumulated in G2 phase of the cell cycle. Data represent means  $\pm$  SEM of  $\geq$ 3 independent experiments, normalized to solvent control. Statistical evaluation was performed using 2-way ANOVA analysis followed by Sidak's multiple comparison test. \* p<0.05, \*\* p<0.01.